EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure

Ibrahim M Ibrahim, Ola Qadi, Osama A A Ahmed, Fatemah Kamel, Rania Magadmi, Sameer Alharthi

Saudi Pharmaceutical Journal · 2026-04 · 34 (2)

DOI: 10.1007/s44446-026-00076-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Saudi Pharmaceutical Journal, online erschienen am 01.04.2026. Verfasst von Ibrahim M Ibrahim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research (DSR) at King Abdulaziz University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ulcerative colitis (UC) is a chronic inflammatory bowel disease resulting in mucosal inflammation and ulceration. Although tofacitinib, a Janus kinase inhibitor, is effective when administered systemically, its clinical use may be limited by systemic adverse effects. Thus, this study aimed to design and evaluate a colon‑targeted tofacitinib delivery system based on sodium alginate beads coated with Eudragit® S‑100 in a dextran sulfate sodium (DSS) induced colitis rat model. Tofacitinib was encapsulated within alginate beads and subsequently coated with Eudragit® S-100 for pH-dependent release. The beads were characterized for size, encapsulation efficiency, stability, and in vitro drug release. Therapeutic efficacy was evaluated in a 30-day DSS colitis model by histopathology, cytokine profiling, and drug concentrations in plasma and colon tissue. The colon-targeted beads exhibited minimal release under acidic gastric conditions and maximum release at the colonic pH. In vivo , the formulation significantly improved disease activity scores, preserved colonic architecture, and significantly reduced pro-inflammatory cytokines levels while increasing IL-10 levels. Colonic drug levels achieved with the formulated beads were substantially higher than those obtained with non‑formulated tofacitinib, accompanied by markedly reduced systemic exposure. As a conclusion, the colon-targeted tofacitinib delivery system may limit systemic exposure relative to conventional oral administration while maintaining therapeutic efficacy in experimental colitis. Nevertheless, comprehensive toxicological and long‑term safety studies are required before definitive conclusions regarding safety can be drawn.

Schlagwörter

Stichwörter der Autor:innen

2 alginates3 colitis4 cytokines5 tofacitinib6 targeted delivery

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Pharmacy, Al-Hada Armed Forces Hospital, Taif, Saudi Arabia.
  • Pharmacy Program, Department of Pharmaceutical Sciences, Batterjee Medical College, 21442, Jeddah, Saudi Arabia.
  • Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. rmagadmi@kau.edu.sa.
  • Inflammatory Bowel Disease Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.

Förderung

  • Deanship of Scientific Research (DSR) at King Abdulaziz University

Zitieren

APA

Ibrahim, I. M., Qadi, O., Ahmed, O. A. A., Kamel, F., Magadmi, R., & Alharthi, S. (2026). Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure. Saudi Pharmaceutical Journal, 34(2). https://doi.org/10.1007/s44446-026-00076-0

Vancouver

Ibrahim IM, Qadi O, Ahmed OAA, Kamel F, Magadmi R, Alharthi S. Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure. Saudi Pharmaceutical Journal. 2026;34(2). doi:10.1007/s44446-026-00076-0

BibTeX
@article{Ibrahim2026,
  author = {Ibrahim, Ibrahim M and Qadi, Ola and Ahmed, Osama A A and Kamel, Fatemah and Magadmi, Rania and Alharthi, Sameer},
  title = {Colon-targeted pH-responsive tofacitinib beads improve ulcerative colitis outcomes with lower systemic exposure},
  journal = {Saudi Pharmaceutical Journal},
  year = {2026},
  volume = {34},
  number = {2},
  doi = {10.1007/s44446-026-00076-0}
}
Kostenlos starten →